Aim: Due to limited information on these genes and to a better understanding of common biomarkers associated with cancer of the digestive tract routes, we aim to evaluated expression level of Olfactomedin4 (OLFM4) and (pro)collagen11A1/COL11A1 genes in people with gastric cancer in Iran.
Background: Gastric cancer is one of the main cause of cancer death. The early prognosis of gastric cancer is still a matter of debate. Human olfactomedin4 (OLFM4) is a glycoprotein that generally known as the antiapoptotic protein. (pro) collagen11A1/COL11A1 codes for the alpha-1 subunit of type XI collagen which exists in extracellular minor fibrillar collagen. In most cases, OLFM4 and COL11A1 are found to be up-regulated in many types of human cancers including gastric cancer.
Methods: 35 tissue samples were collected including 25 sample of patients with intestinal gastric cancer and 10 healthy controls. Expression level of OLFM4 and COL11A1 genes identified by using RGQ software. For analysis of real time-PCR products, Rotor-Gene Q series software was used.
Results: Our finding showed that expression level of OLFM4 was significantly upregulated and COL11A1 did not show any significant difference in expression level in Iranian population with gastric cancer samples compared with those in normal samples.
Conclusion: The results recommend that expression profiling of OLFM4 can be used for diagnosis of gastric cancer, and OLFM4 seems to be used as a biomarker for the diagnosis of gastric cancer. Regarding to our result, unlike some studies, COL11A1 did not show any significant difference between normal and tumor tissue which could explain ethological role in distribution of gastric cancer
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. 2012.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E86.
Pazdur R. Cancer management: a multidisciplinary approach, medical, surgical & radiation oncology: Cmp; 2004.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-7.
Hajizadeh N, Pourhoseingholi MA, Baghestani AR, Abadi A, Zali MR. Name of Journal: World Journal of Gastrointestinal Oncology ESPS Manuscript NO: 29510 Manuscript Type: Original Article Observational Study Bayesian adjustment for over-estimation and under-estimation of gastric cancer incidence across Iranian provinces.
Delpisheh A, Veisani Y, Sayehmiri K, Rahimi E. Smoking and Histological Factors Influencing Long-term Survival of Gastric Carcinoma in Consecutive Patient Series. Middle East Journal of Cancer. 2014;5(3):129-35.
Zhang J, Liu W-L, Tang DC, Chen L, Wang M, Pack SD, et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 2002;283(1):83-93.
Snyder DA, Rivers AM, Yokoe H, Menco BPM, Anholt RR. Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry. 1991;30(38):9143-53.
Kulkarni NH, Karavanich CA, Atchley WR, Anholt RR. Characterization and differential expression of a human gene family of olfactomedin-related proteins. Genet Res. 2000;76(01):41-50.
Chin KL, Aerbajinai W, Zhu J, Drew L, Chen L, Liu W, et al. The regulation of OLFM4 expression in myeloid precursor cells relies on NF??B transcription factor. Br J Haematol. 2008;143(3):421-32.
Liu W, Chen L, Zhu J, Rodgers GP. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 2006;312(10):1785-97.
Kobayashi D, Koshida S, Moriai R, Tsuji N, Watanabe N. Olfactomedin 4 promotes S?phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 2007;98(3):334-40.
Liu W, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 2008;14(4):1041-9.
Li H, Rodriguez-Canales J, Liu W, Zhu J, Hanson JC, Pack S, et al. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer. The American journal of pathology. 2013;183(4):1329-38.
Andreu P, Perret C, Romagnolo B. Wnt and gastrointestinal stem cells: dangerous connections. 2005.
Clevers H. Stem cells, asymmetric division and cancer. Nat Genet. 2005;37(10):1027-9.
Guezguez A, Paré F, Benoit YD, Basora N, Beaulieu J-F. Modulation of stemness in a human normal intestinal epithelial crypt cell line by activation of the WNT signaling pathway. Exp Cell Res. 2014;322(2):355-64.
Seko N, Oue N, Noguchi T, Sentani K, Sakamoto N, Hinoi T, et al. Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer. Exp Ther Med. 2010;1(1):73-8.
Koshida S, Kobayashi D, Moriai R, Tsuji N, Watanabe N. Specific overexpression of OLFM4GW112/hGC? 1 mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 2007;98(3):315-20.
Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis & tissue repair. 2012;5(1):15.
Vázquez-Villa F, García-Ocaña M, Galván JA, García-Martínez J, García-Pravia C, Menéndez-Rodríguez P, et al. COL11A1/(pro) collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Tumor Biology. 2015;36(4):2213-22.
Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, et al. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Archives of Otolaryngology–Head & Neck Surgery. 2004;130(3):295-302.
Galván JA, García-Martínez J, Vázquez-Villa F, García-Ocaña M, García-Pravia C, Menéndez-Rodríguez P, et al. Validation of COL11A1/procollagen 11A1 expression in TGF-?1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. BMC Cancer. 2014;14(1):867.
Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, et al. Autocrine TGF-? and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences. 2010;107(46):20009-14.
Margolin DA, Silinsky J, Grimes C, Spencer N, Aycock M, Green H, et al. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1?/CXCR4 paracrine signaling. Neoplasia. 2011;13(9):874IN27-86IN30.
Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol. 2011;89(1):31-9.
Polanska UM, Orimo A. Carcinoma?associated fibroblasts: Non?neoplastic tumour?promoting mesenchymal cells. J Cell Physiol. 2013;228(8):1651-7.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010;2.
. Available from: https://www.cancer.org/cancer/stomach-cancer/about/what-is-stomach-cancer.html.
Enayatrad M, Salehiniya H. Trends in gastric cancer incidence in Iran. Journal of Mazandaran University of Medical Sciences. 2014;24(114):8-16.
Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis. 2010;28(4-5):600-3.
Sun H. Identification of key genes associated with gastric cancer based on DNA microarray data. Oncol Lett. 2016;11(1):525-30.
Liu W, Yan M, Liu Y, McLeish KR, Coleman WG, Rodgers GP. Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of Staphylococcus aureus and Escherichia coli in mice. The Journal of Immunology. 2012;189(5):2460-7.
Liu W, Yan M, Sugui JA, Li H, Xu C, Joo J, et al. Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. The Journal of clinical investigation. 2013;123(9):3751.
Liu W, Zhu J, Cao L, Rodgers G. Expression of hGC?1 is correlated with differentiation of gastric carcinoma. Histopathology. 2007;51(2):157-65.
Zeng L-C, Han Z-G, Ma W-J. Elucidation of subfamily segregation and intramolecular coevolution of the olfactomedin?like proteins by comprehensive phylogenetic analysis and gene expression pattern assessment. FEBS Lett. 2005;579(25):5443-53.
Moreno TA, Bronner-Fraser M. The secreted glycoprotein Noelin-1 promotes neurogenesis in Xenopus. Dev Biol. 2001;240(2):340-60.
Liu W, Rodgers GP. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Cancer Metastasis Rev. 2016:1-12.
Anholt RR. Olfactomedin proteins: central players in development and disease. Frontiers in cell and developmental biology. 2014;2.
Liu W, Li H, Hong S, Piszczek G, Chen W, Rodgers G. Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice. Oncogene. 2016;35(40):5237.
Li H, Liu W, Chen W, Zhu J, Deng C-X, Rodgers GP. Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway. Sci Rep. 2015;5.
Liu W, Lee HW, Liu Y, Wang R, Rodgers GP. Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2?-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood. 2010;116(23):4938-47.
Liu W, Rodgers GP. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Cancer Metastasis Rev. 2016;35(2):201-12.
Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, et al. Serum olfactomedin 4 (GW112, hGC?1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009;125(10):2383-92.
Luo Z, Zhang Q, Zhao Z, Li B, Chen J, Wang Y. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol. 2011;137(11):1713-20.
Jang BG, Lee BL, Kim WH. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer. Virchows Arch. 2015;467(3):285-94.
Yadegar A, Alebouyeh M, Lawson AJ, Mirzaei T, Mojarad EN, Zali MR. Differentiation of non-pyloriHelicobacter species based on PCR–restriction fragment length polymorphism of the 23S rRNA gene. World Journal of Microbiology and Biotechnology. 2014;30(6):1909-17.
Yadegar A, Alebouyeh M, Zali MR. Analysis of the intactness of Helicobacter pylori cag pathogenicity island in Iranian strains by a new PCR-based strategy and its relationship with virulence genotypes and EPIYA motifs. Infect Genet Evol. 2015;35:19-26.
Shinozaki S, Nakamura T, Iimura M, Kato Y, Iizuka B, Kobayashi M, et al. Upregulation of Reg 1? and GW112 in the epithelium of inflamed colonic mucosa. Gut. 2001;48(5):623-9.
Zhang X, Huang Q, Yang Z, Li Y, Li C-Y. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 2004;64(7):2474-81.
Canty EG, Kadler KE. Procollagen trafficking, processing and fibrillogenesis. J Cell Sci. 2005;118(7):1341-53.
Fuentes Martínez N, García Pravia MdC, García Ocaña M, Menéndez Rodríguez MP, Amo Iribarren Jd, Suárez Fernández L, et al. Overexpression of proCOL11A1 as a stromal marker of breast cancer. Histol Histopathol, 30. 2015.
Erkan M, Weis N, Pan Z, Schwager C, Samkharadze T, Jiang X, et al. Organ-, inflammation-and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer. 2010;9(1):88.
Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, Wilborn TW, et al. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs. Screening by DNA microarrays. Inflamm Bowel Dis. 2004;10(1):1-14.
Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, et al. Gene expression analysis of early and advanced gastric cancers. Oncogene. 2007;26(29):4284-94.